Patents Represented by Attorney, Agent or Law Firm Ramsey R. Stewart
  • Patent number: 6273908
    Abstract: A stent having cavities has been developed that can be quickly and easily used in a wide variety of situations, that keeps vessels open with a minimum degree of recoil and shortening lengthwise, that is flexible and can be delivered to the most distal lesion, and that can continuously deliver anticoagulant or other biologically active agents for an extended period directly at the site of stent placement. The stent of the present invention includes at least one flexible, serpentine backbone, and a plurality of opposing, outwardly-projecting appendages on said backbone, wherein said stent has a substantially circular cross-section.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: August 14, 2001
    Inventor: Robert Ndondo-Lay
  • Patent number: 6265173
    Abstract: In accordance with the present invention, it has been discovered that various members of the steroid/thyroid superfamily of receptors can interact with the insect-derived ultraspiracle receptor, to form multimeric species. Accordingly, the interaction of at least one member of the steroid/thyroid superfamily of receptors with at least the dimerization domain of the ultraspiracle receptor modulates the ability of said member of the steroid/thyroid superfamily of receptors to trans-activate transcription of genes maintained under hormone expression control in the presence of the cognate ligand for said member of the superfamily.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 24, 2001
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael B. Mc Keown, Anthony E. Oro, William A. Segraves, Tso-Pang Yao
  • Patent number: 6184353
    Abstract: Farnesyl pyrophosphate, the metabolically active form of farnesol, is a key precursor in the synthesis of cholesterol, carotenoids, steroid hormones, bile acids and other molecules involved in cellular growth and metabolism. A nuclear receptor has been identified that is transcriptionally activated by farnesol and related molecules. This novel signaling pathway can be modulated by the use of key metabolic intermediates (or analogs and/or derivatives thereof) as transcriptional regulatory signals.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: February 6, 2001
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Barry M. Forman, Cary A. Weinberger
  • Patent number: 5750132
    Abstract: The present invention relates to methods of lessening the severity and frequency of adverse effects associated with administration of extracellular hemoglobin comprising administration of a smooth muscle relaxant. Preferred smooth muscle relaxants are terbutaline and nifedipine, which can be administered in a prophylactic treatment, responsive regimented treatment or responsive intermittent treatment.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: May 12, 1998
    Assignee: Somatogen, Inc.
    Inventor: Michael J. Gerber